Chemomab Therapeutics Ltd DRC - Asset Resilience Ratio
Chemomab Therapeutics Ltd DRC (CMMB) has an Asset Resilience Ratio of 24.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CMMB total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Chemomab Therapeutics Ltd DRC's Asset Resilience Ratio has changed over time. See Chemomab Therapeutics Ltd DRC book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Chemomab Therapeutics Ltd DRC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Chemomab Therapeutics Ltd DRC.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.08 Million | 24.92% |
| Total Liquid Assets | $3.08 Million | 24.92% |
Asset Resilience Insights
- Good Liquidity Position: Chemomab Therapeutics Ltd DRC maintains a healthy 24.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Chemomab Therapeutics Ltd DRC Industry Peers by Asset Resilience Ratio
Compare Chemomab Therapeutics Ltd DRC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Chemomab Therapeutics Ltd DRC (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Chemomab Therapeutics Ltd DRC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 48.31% | $8.20 Million | $16.96 Million | +0.94pp |
| 2023-12-31 | 47.37% | $10.49 Million | $22.15 Million | -13.88pp |
| 2022-12-31 | 61.25% | $26.37 Million | $43.06 Million | -10.20pp |
| 2021-12-31 | 71.44% | $45.98 Million | $64.35 Million | +71.25pp |
| 2020-12-31 | 0.19% | $24.00K | $12.48 Million | -4.11pp |
| 2015-12-31 | 4.30% | $151.12K | $3.52 Million | -- |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing ch… Read more